{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:52Z","timestamp":1792068892016,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LQ24H300012"],"award-info":[{"award-number":["LQ24H300012"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFA1506403"],"award-info":[{"award-number":["2023YFA1506403"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["W2412100"],"award-info":[{"award-number":["W2412100"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["42276137"],"award-info":[{"award-number":["42276137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404506"],"award-info":[{"award-number":["82404506"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmc.2026.118789","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:15:52Z","timestamp":1788045352000},"page":"118789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel phenylindole derivatives as P-gp inhibitors to overcome multidrug resistance in MCF-7\/ADR cells"],"prefix":"10.1016","volume":"143","author":[{"given":"Zhikun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhe","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherien M.","family":"Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118789_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118449","article-title":"Indole hybrids: emerging therapeutic candidates for breast cancer (2023\u20132025)","volume":"303","author":"Huang","year":"2026","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2026.118789_bb0010","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118789_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1348076","article-title":"Natural products reverse cancer multidrug resistance","volume":"15","author":"Zou","year":"2024","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.bmc.2026.118789_bb0020","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bmc.2026.118789_bb0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/cells2030545","article-title":"DNA methylation and apoptosis resistance in cancer cells","volume":"2","author":"Hervouet","year":"2013","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2026.118789_bb0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semcancer.2019.04.001","article-title":"Emerging role of PI3K\/AKT in tumor-related epigenetic regulation","volume":"59","author":"Yang","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bmc.2026.118789_bb0035","doi-asserted-by":"crossref","unstructured":"Y. Yang, M. Zhang, Y. Wang. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Natl Cancer Cent 2022, 2(4), 277\u2013290. DOI:https:\/\/doi.org\/10.1016\/j.jncc.2022.09.002.","DOI":"10.1016\/j.jncc.2022.09.002"},{"issue":"1","key":"10.1016\/j.bmc.2026.118789_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.bmc.2026.118789_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12943-022-01524-w","article-title":"CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1\/P-gp mediated multi-drug resistance (MDR) in cancer cells","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2026.118789_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41392-019-0059-4","article-title":"EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer","volume":"4","author":"Yang","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.bmc.2026.118789_bb0055","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","article-title":"Understanding and overcoming multidrug resistance in cancer","volume":"22","author":"Ge","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.bmc.2026.118789_bb0060","first-page":"710","article-title":"Recent advances in the search of BCRP- and dual P-gp\/BCRP-based multidrug resistance modulators","volume":"2","author":"Dei","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.bmc.2026.118789_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2026.178546","article-title":"Research progress on the mechanisms of action, pharmacological activities and clinical application of P-glycoprotein inhibitors","volume":"1015","author":"Gu","year":"2026","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2026.118789_bb0070","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-biochem-011520-105201","article-title":"Structural and mechanistic principles of ABC transporters","volume":"89","author":"Thomas","year":"2020","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118789_bb0075","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3390\/ijms22041593","article-title":"The role of the ATP-binding cassette A1 (ABCA1) in human disease","volume":"22","author":"Jacobo-Albavera","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118789_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bmc.2026.118789_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112153","article-title":"Verapamil and tangeretin enhances the M1 macrophages to M2 type in lipopolysaccharide-treated mice and inhibits the P-glycoprotein expression by downregulating STAT1\/STAT3 and upregulating SOCS3","volume":"133","author":"Kundu","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.bmc.2026.118789_bb0090","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ijc.2910560523","article-title":"Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines","volume":"56","author":"Muller","year":"1994","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.bmc.2026.118789_bb0095","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ejca.2004.01.024","article-title":"Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein","volume":"40","author":"Kemper","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2026.118789_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","article-title":"Biochemical, cellular, and pharmacological aspects of the multidrug transporter","volume":"39","author":"Ambudkar","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.bmc.2026.118789_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1006046201497","article-title":"PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance","volume":"17","author":"Atadja","year":"1998","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"10.1016\/j.bmc.2026.118789_bb0110","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/jop.2018.0041","article-title":"Dose optimization based on population pharmacokinetic modeling of high-dose cyclosporine, a P-glycoprotein inhibitor, in combination with systemic chemotherapy in pediatric patients with retinoblastoma","volume":"34","author":"Ree","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.bmc.2026.118789_bb0115","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/1078-0432.CCR-0914-3","article-title":"VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein","volume":"10","author":"Minderman","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.bmc.2026.118789_bb0120","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1995.13.8.1985","article-title":"Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy","volume":"13","author":"Wilson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118789_bb0125","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","article-title":"Biochemistry of multidrug resistance mediated by the multidrug transporter","volume":"62","author":"Gottesman","year":"1993","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118789_bb0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.bmc.2026.118789_bb0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/dmd.115.067785","article-title":"Tariquidar is an inhibitor and not a substrate of human and mouse P-glycoprotein","volume":"44","author":"Weidner","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.bmc.2026.118789_bb0140","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1021\/acs.jmedchem.0c01826","article-title":"Discovery of encequidar, first-in-class intestine specific P-glycoprotein inhibitor","volume":"64","author":"Smolinski","year":"2021","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118789_bb0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14737140.7.4.447","article-title":"Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor","volume":"7","author":"Fox","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.bmc.2026.118789_bb0150","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nucmedbio.2009.03.004","article-title":"Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats","volume":"36","author":"Luurtsema","year":"2009","journal-title":"Nucl Med Biol"},{"issue":"8","key":"10.1016\/j.bmc.2026.118789_bb0155","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/CAD.0b013e32832ec041","article-title":"The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells","volume":"20","author":"Yde","year":"2009","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.bmc.2026.118789_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106997","article-title":"Recent developments of P-glycoprotein inhibitors and its structure-activity relationship (SAR) studies","volume":"143","author":"Zhao","year":"2024","journal-title":"Bioorg Chem"},{"issue":"8","key":"10.1016\/j.bmc.2026.118789_bb0165","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1021\/acs.jmedchem.6b01787","article-title":"Design, synthesis, and pharmacological characterization of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine derivatives: novel inhibitors reversing P-glycoprotein-mediated multidrug resistance","volume":"60","author":"Qiu","year":"2017","journal-title":"J Med Chem"},{"issue":"41","key":"10.1016\/j.bmc.2026.118789_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400340","article-title":"Zosuquidar promotes antitumor immunity by inducing autophagic degradation of PD-L1","volume":"11","author":"Ding","year":"2024","journal-title":"Adv Sci"},{"issue":"11\u221212","key":"10.1016\/j.bmc.2026.118789_bb0175","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/sj.bjc.6690267","article-title":"In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance","volume":"79","author":"Mistry","year":"1999","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.bmc.2026.118789_bb0180","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1021\/acs.jmedchem.6b01879","article-title":"Exploration of 2-((pyridin-4-ylmethyl)amino)nicotinamide derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance","volume":"60","author":"Qiu","year":"2017","journal-title":"J Med Chem"},{"issue":"19","key":"10.1016\/j.bmc.2026.118789_bb0185","doi-asserted-by":"crossref","first-page":"14895","DOI":"10.1021\/acs.jmedchem.1c01452","article-title":"Discovery of new 4-indolyl quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors","volume":"64","author":"Yuan","year":"2021","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2026.118789_bb0190","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1021\/acs.jmedchem.1c00246","article-title":"Structure-based discovery of pyrimidine aminobenzene derivatives as potent oral reversal agents against P-gp- and BCRP-mediated multidrug resistance","volume":"64","author":"Qiu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118789_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114231","article-title":"Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel","volume":"233","author":"Shi","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118789_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108854","article-title":"Rational discovery of novel tetrahydroisoquinoline-indole derivatives as potent P-glycoprotein inhibitor against multidrug resistance in MCF-7\/ADR cell","volume":"164","author":"Yang","year":"2025","journal-title":"Bioorg Chem"},{"issue":"5","key":"10.1016\/j.bmc.2026.118789_bb0205","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1039\/D6MD00030D","article-title":"Rational discovery of novel phenylindole-bisamide derivatives as potent P-glycoprotein inhibitors for cancer multidrug resistance","volume":"17","author":"Yang","year":"2026","journal-title":"RSC Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2026.118789_bb0210","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1021\/acs.jmedchem.2c01999","article-title":"Novel benzo five-membered heterocycle derivatives as P-glycoprotein inhibitors: design, synthesis, molecular docking, and anti-multidrug resistance activity","volume":"66","author":"Yang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118789_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"10.1016\/j.bmc.2026.118789_bb0220","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.bmc.2026.118789_bb0225","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1021\/acs.jmedchem.8b00335","article-title":"Discovery of 5-Cyano-6-phenylpyrimidin derivatives containing an Acylurea moiety as orally bioavailable reversal agents against P-glycoprotein-mediated multidrug resistance","volume":"61","author":"Wang","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118789_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116039","article-title":"Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance","volume":"264","author":"Xue","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118789_bb0235","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ejca.2003.09.036","article-title":"Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy","volume":"40","author":"Walker","year":"2004","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.bmc.2026.118789_bb0240","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41598-018-19325-x","article-title":"Targeted inhibitors of p-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells","volume":"8","author":"Nanayakkara","year":"2018","journal-title":"Sci Rep"},{"issue":"42","key":"10.1016\/j.bmc.2026.118789_bb0245","doi-asserted-by":"crossref","first-page":"26245","DOI":"10.1073\/pnas.2010264117","article-title":"Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1","volume":"117","author":"Nosol","year":"2020","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:37:51Z","timestamp":1792067871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":49,"alternative-id":["S0968089626002452"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118789","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel phenylindole derivatives as P-gp inhibitors to overcome multidrug resistance in MCF-7\/ADR cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118789"}}